Mineralys Therapeutics, Inc.
MLYS
$14.89
$0.2751.88%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 43.65% | 42.53% | 78.79% | 62.19% | 53.08% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 3.49% | 25.69% | 86.81% | 128.77% | 187.05% |
Operating Income | -3.49% | -25.69% | -86.81% | -128.77% | -187.05% |
Income Before Tax | -5.51% | -33.97% | -100.69% | -147.55% | -237.81% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -5.51% | -33.97% | -100.69% | -147.55% | -237.81% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -5.51% | -33.97% | -100.69% | -147.55% | -237.81% |
EBIT | -3.49% | -25.69% | -86.81% | -128.77% | -187.05% |
EBITDA | -3.48% | -25.68% | -- | -- | -- |
EPS Basic | 20.43% | -13.15% | -61.06% | -98.42% | -172.10% |
Normalized Basic EPS | 20.45% | -13.13% | -61.05% | -98.46% | -172.08% |
EPS Diluted | 20.43% | -13.15% | -61.06% | -98.42% | -172.10% |
Normalized Diluted EPS | 20.45% | -13.13% | -61.05% | -98.46% | -172.08% |
Average Basic Shares Outstanding | 32.61% | 18.40% | 24.60% | 24.75% | 24.15% |
Average Diluted Shares Outstanding | 32.61% | 18.40% | 24.60% | 24.75% | 24.15% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |